• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Simeprevir Responsible for Deaths in Japanese Hepatitis C Patients

Article

A spike in the blood bilirubin levels resulting in hepatic dysfunction and/or renal impairment was determined as the cause of death.

Sovriad (simeprevir sodium) was launched in Japan in December 2013. Of an estimated 18,900 patients taking the medication for hepatitis C infection, 3 deaths have been reported till October 2014. Hepatic and or renal impairement resulting from a significant increase in blood bilirubin levels was identified as the cause of death. The Pharmaceutical and Medical Devices Agency in Japan subsequently issued a "Dear Healthcare Professional Letter" and also asked Janssen to update the Warnings Subsection in the Precautions Section within the label.

Link to the letter issued by PMDA: http://bit.ly/1waEwBf

Related Videos
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Rashon Lane, PhD, MA
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.